Salute e Benessere

Top 20 Personal Care Ingredients Companies, Worldwide 2023: MarketsandMarkets…

The growing spending power and changing lifestyles of individuals in developing nations are the key factors driving the market for personal care ingredients. The market is also being driven by the quick expansion of components for personal care products. Government laws against cosmetics and healthcare products are the market's limiting element. High market potential in emerging nations is also anticipated to fuel market expansion in the near future. The growing spending power and changing...

Mammotome Launches the HydroMARK™ Plus Breast Biopsy Site Marker, an Innovation…

The HydroMARK™ Plus marker offers the same unmatched benefits as the original HydroMARK™ marker portfolio, which features exclusive hydrogel technology. The hydrogel-based carrier hydrates more than 200% original size and becomes strikingly anechoic within 24 hours, and lasts up to 12 months, enabling long-term ultrasound visibility, even in patients undergoing Neoadjuvant Chemotherapy (NACT).6,7 This feature when combined with the HydroMARK™ Plus shape, a portion of which is outside of the…

Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical…

(NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information: ( https://gedicube.com/news ). “We are excited about the appointment of Dr. Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a seasoned expert in clinical medicine and digital health, he could enhance the capabilities of GEDi Cube to make a difference in the lives of people at risk of or suffering from serious illnesses...

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease…

PIM kinases are gateway kinases in multiple immune cell lineages (including B and T effector cells) driving excessive inflammation. Elevated PIM kinase may further contribute to the formation and maintenance of tertiary lymphoid structures (TLS) which are associated with disease severity and progression. Autoimmune diseases impact over 23 million in US alone. Despite recent progress and novel treatment options, significant unmet needs remain due to poor response rates and adverse...

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25…

Contract Research, Development & Manufacturing Organization (CRO-CDMO), entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development. Marking the entry into its 25 thyear, the Chairman Dr. K. Ranga Raju...

Inhalis Therapeutics SA Achieves Key Milestone with Patent Application Filing

About Inhalis Therapeutics SA About Inhalis Therapeutics SA Inhalis Therapeutics SA is committed to develop breakthrough inhaled treatments for life-threatening disorders. Solid science and industry-leading delivery technology are combined with an experienced management team to research and develop new inhaled treatments for Idiopathic Pulmonary Fibrosis and other diseases. The lead asset, INHAL-101, a ground-breaking solution for IPF, is poised to initiate clinical trials in Q4/2024...

Save the date: Implantica Capital Markets Day 2023

More information will be made available at a later stage. More information will be made available at a later stage. For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs Officer Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica.com Implantica is listed on Nasdaq First North Premier Growth Market inStockholm. The company's Certified Adviser is FNCA Sweden AB,info@fnca.se The information was sent for publication, through the agency...

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust…

"We remain focused on helping those suffering from substance use disorders and mental illness," said Mark Crossley, Chief Executive Officer. "Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders." "We remain focused on helping those suffering from substance use disorders and mental illness," saidMark Crossley, Chief Executive Officer. "Resolving these legacy legal…

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal…

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer – A trend toward improvement in overall survival was observed at first interim analysis – Findings will be presented at an upcoming medical meeting and discussed with health authorities globally ALAMEDA, Calif...

LG OFFERS ONE-STOP LAUNDRY SOLUTION WITH NEW SECOND-GEN LG SIGNATURE…

The stylish 27-inch Washer-Dryer with Heat Pump features LG SIGNATURE's seamless, elegant design, and boasts ample room for getting clothes clean and dry with a 25-kg washing capacity, and 13-kg for drying. A genuine space-saver with a large capacity, LG's washer-dryer also integrates the innovative TWINWash™ feature, a small washer located below the main drum that's ideal for cleaning delicates or daily workout gear. The ability to wash and dry makes the company's new all-in-one model…

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 04082023_trading_in_shares_NP,_Aage_and_Johanne_Louis-Hansens_Fond_and_Coloplast_Holding_ApS

Major shareholder notification

Major shareholder notification Reference is made to the press release issued by Coloplast A/S on 21 June 2023 regarding the intention of Coloplast A/S' largest shareholders, Niels Peter Louis-Hansen, and Aage og Johanne Louis-Hansens Fond to co-found a new holding company for the purpose of holding shares in Coloplast A/S. Coloplast A/S hereby announces that on 18 August 2023, Coloplast A/S has received the following major shareholder notification: Coloplast Holding ApS holds 52...

Progress share buy-back program Fagron

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 August 2023 – 6PM CET Progress share buy-back program Fagron In the period from 14 August 2023 through 18 August 2023, Fagron purchased 34,900 of its owns shares at an average price of €16.17 per share corresponding to a total amount of €564,264.06. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron's obligations under its long term incentive scheme, which was...

Evaxion Announces Business Update and Second Quarter 2023 Financial Results

Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023A novel proprietary genetic vaccine adjuvant was presented at Evaxion's R&D Day in May. The technology is an integral part of the next-generation cancer vaccine, EVX-03, planned for phase 1 clinical trial application in Q4 2023*Promising results on EVX-B1, a Staphylococcus aureus vaccine candidate, were presented at the Staphylococcal Diseases Gordon Research Conference...

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI…

The partnership between 3Z and biotx.ai aims to establish a robust bridge from animal discovery studies to human clinical trials. By utilizing comprehensive AI-powered human genetics-based modelling, the involvement of the lead therapeutic targets in ADHD will be thoroughly explored. This study will provide insights into the targets' effects on the disorder, predict potential effects on other diseases or disorders, and assess metabolic changes. Real-world zebrafish measurements will be compared…

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624 Browse in-depth TOC on "Clinical Trial Imaging Market" 111 - Tables 38 - Figures 179 - Pages Clinical Trial Imaging Market Scope: The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022 ...

Biomedical Textiles Market to Reach $30.3 Billion, Globally, by 2032 at 6.2%…

Biomedical textiles have been in routine clinical use to ease healing for a very long time. These are widely used in neurovascular products, orthopedic sutures, orthopedic implants, heart valves, vascular grafts, annuloplasty rings, catheter-based delivery systems, pledgets, small joint repair, tissue scaffolds, scoliosis treatment, cerclage cables, spinal stabilization products, and an array of robotic surgery products. Biomedical textiles have been in routine clinical use to ease healing…

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to…

NEW YORK and LONDON, Aug.18, 2023(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the establishment of a Boston Seaport area office that is the company's U.S. headquarters. The office supports Akari's current expansion of operations in preparation for the start of enrollment in two registrational nomacopan Phase 3 clinical trials in pediatric and adult...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 18August 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members,...

Navamedic ASA - Mandatory notification of trade by primary insider

Kathrine Gamborg Andreassen, CEO of Navamedic, has today, on August 18 2023, exercised 25,000 share options in the Company under her options agreement from 2020 and subscribed for 25,000 new shares in the Company. Following the option exercise and subscription of the new shares, Kathrine Gamborg Andreassen holds 691 668 shares and 280,000 options in the Company. Kathrine Gamborg Andreassen, CEO of Navamedic, has today, onAugust 182023, exercised 25,000 share options in the Company under...

NAVAMEDIC ASA: Resolution to increase the share capital in connection with…

For further information, please contact: For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:kathrine@navamedic.com Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:lars.hjarrand@navamedic.com About Navamedic ASA: Navamedic ASA is a Nordic full-service provider of high-quality products to hospitals and through pharmacies. Navamedic meets the specific needs of patients and consumers by leveraging its...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA…

"We are delighted to have been granted priority review by the FDA, which brings us one step closer to hopefully being able to provide TARPEYO to all patients at risk of progression and provide physicians with a tool to target the source of this disease to slow kidney function decline," said Renee Aguiar-Lucander, CEO of Calliditas. "The significant eGFR treatment benefit observed across the entire study population provides further evidence that TARPEYO can be disease-modifying…

Interim report: SciBase

The second quarter in figures The second quarter in figures The half year in figures Important events during the quarter Important events after the end of the period Financial overview This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was originally submitted for publication, through the agency of the contact person set out below, at 08.00 CET onAugust 18, 2023. This...

Beyond Silver - IDTechEx Examines Alternative Antimicrobial Strategies

One of the approaches companies have taken in developing antimicrobial technologies beyond silver is to look towards nature for inspiration. Relatively few companies are active in this space, and each focuses on developing their own bio-based antimicrobial material. Recent product launches from major players may help to draw more attention to these bio-sourced alternatives, and the marketing often focuses on the materials' sustainability and eco-friendliness. Examples of commercialized products…

Altri Comunicati